Share capital increase registered
(Oslo, 17 August 2015) With reference to the announcement made on 23 June 2015 regarding issuance of shares to members of the Board of Directors of Bionor as resolved by the Annual General Meeting on 13 May 2015, the share capital increase has now been registered in the Companies Register.
The new share capital of the Company is NOK 62,327,487.50 divided into 249,309,950 shares with par value NOK 0.25.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Jørgen F. Ravn, VP Investor Relations & Communications, +45 2030 3903, email@example.com
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company's focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma’s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. Bionor Pharma is headquartered in Oslo, Norway and is listed on Oslo Børs, under the ticker BIONOR. More information about Bionor is available at www.bionorpharma.com.